Benjamin T. Dake net worth and biography

Benjamin Dake Biography and Net Worth

Insider of Aerovate Therapeutics

Benjamin T. Dake was the founder of Aerovate Therapeutics, Inc. since 2018, holding the title of President, Chief Operating Officer & Secretary from 2021 to 2024. Former job includes Associate at RA Capital Management LP from 2015 to 2019.

Education includes undergraduate and graduate degrees from The University of Nebraska-Lincoln and a doctorate from Tufts University School of Medicine.

What is Benjamin T. Dake's net worth?: The estimated net worth of Benjamin T. Dake is at least $432.00 as of April 17th, 2024. Dake owns 36 shares of Aerovate Therapeutics stock worth more than $432 as of December 5th. This net worth evaluation does not reflect any other investments that Dake may own. Additionally, Dake receives an annual salary of $435,500.00 as Insider at Aerovate Therapeutics. Learn More about Benjamin T. Dake's net worth.
How old is Benjamin T. Dake?: Dake is currently 48 years old. There are 5 older executives and no younger executives at Aerovate Therapeutics. The oldest executive at Aerovate Therapeutics is Dr. Ralph W. Niven M.B.A., M.R, Ph.D., Pharm.S, Chief Scientific Officer, who is 64 years old. Learn More on Benjamin T. Dake's age.
What is Benjamin T. Dake's salary?: As the Insider of Aerovate Therapeutics, Inc., Dake earns $435,500.00 per year. There are 5 executives that earn more than Dake. The highest earning executive at Aerovate Therapeutics is Mr. Timothy P. Noyes M.B.A., CEO & Director, who commands a salary of $936,900.00 per year. Learn More on Benjamin T. Dake's salary.
How do I contact Benjamin T. Dake?: The corporate mailing address for Dake and other Aerovate Therapeutics executives is , , . Aerovate Therapeutics can also be reached via phone at 617-443-2400 and via email at [email protected]. Learn More on Benjamin T. Dake's contact information.
Has Benjamin T. Dake been buying or selling shares of Aerovate Therapeutics?: Benjamin T. Dake has not been actively trading shares of Aerovate Therapeutics within the last three months. Most recently, Benjamin T. Dake sold 195 shares of the business's stock in a transaction on Wednesday, April 17th. The shares were sold at an average price of $782.95, for a transaction totalling $152,675.25. Following the completion of the sale, the insider now directly owns 36 shares of the company's stock, valued at $28,186.20. Learn More on Benjamin T. Dake's trading history.
Who are Aerovate Therapeutics' active insiders?: Aerovate Therapeutics' insider roster includes Benjamin Dake (Insider), cormorant Lp (Insider), and Timothy Noyes (CEO). Learn More on Aerovate Therapeutics' active insiders.

Benjamin T. Dake Insider Trading History at Aerovate Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/17/2024	Sell	195	$782.95	$152,675.25	36
4/1/2024	Sell	95	$1,118.95	$106,300.25	36
3/27/2024	Sell	316	$978.95	$309,348.20	36
3/25/2024	Sell	98	$980.35	$96,074.30	36
11/27/2023	Sell	357	$568.40	$202,918.80	36
11/24/2023	Sell	142	$550.90	$78,227.80	36
11/22/2023	Sell	268	$530.95	$142,294.60	36
9/6/2023	Sell	112	$527.10	$59,035.20	36
8/7/2023	Sell	293	$543.20	$159,157.60	36
7/6/2023	Sell	293	$583.10	$170,848.30	36
5/8/2023	Sell	293	$763.00	$223,559.00	36
4/6/2023	Sell	293	$635.95	$186,333.35	45
3/6/2023	Sell	293	$830.55	$243,351.15	45
2/6/2023	Sell	293	$860.65	$252,170.45	45
1/6/2023	Sell	293	$909.30	$266,424.90	45
11/11/2022	Sell	177	$724.15	$128,174.55
11/8/2022	Sell	239	$633.15	$151,322.85	45
10/17/2022	Sell	119	$705.60	$83,966.40
10/14/2022	Sell	3	$701.75	$2,105.25
10/10/2022	Sell	141	$591.15	$83,352.15
10/7/2022	Sell	300	$560.35	$168,105.00
9/12/2022	Sell	214	$606.55	$129,801.70
9/8/2022	Sell	89	$637.00	$56,693.00
9/6/2022	Sell	261	$648.55	$169,271.55
8/16/2022	Sell	600	$805.00	$483,000.00
8/11/2022	Sell	38	$837.55	$31,826.90
8/8/2022	Sell	198	$861.70	$170,616.60

Benjamin T. Dake Buying and Selling Activity at Aerovate Therapeutics

Aerovate Therapeutics Company Overview

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $12.00

$11.32

$12.40

50 Day Range

MA: $10.13

$8.06

$12.82

2 Week Range

Now: $12.00

$56.35

$105.00

Volume

246,525 shs

Average Volume

12,438 shs

Market Capitalization

$347.82 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95

Benjamin Dake Biography and Net Worth

What is Benjamin T. Dake's net worth?

How old is Benjamin T. Dake?

What is Benjamin T. Dake's salary?

How do I contact Benjamin T. Dake?

Has Benjamin T. Dake been buying or selling shares of Aerovate Therapeutics?

Who are Aerovate Therapeutics' active insiders?